Clinical trial

Allopurinol Impact on Cirrhosis Related Complications

Name

allopurinol in cirrhosis

Description

The study aims to compare the potential benefit of allopurinol in reducing the risk of developing cirrhosis-related complications, delaying the onset of hepatocellular carcinoma, and improving survival. Furthermore, the study aims to evaluate their impact on parents' related quality of life

Trial arms

Trial start

2022-06-15

Estimated PCD

2023-02-15

Trial end

2023-03-01

Status

Completed

Phase

Early phase I

Treatment

Placebo

not containing drugs

Arms:

placebo

Allopurinol 300 MG

a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation

Arms:

allopurinol

Size

100

Primary endpoint

morbidities

6 moths

Eligibility criteria

Inclusion Criteria: * ge 18 to 75 years old Both sex Adults with cirrhosis in a stable conditions Exclusion Criteria: * Active SBP Renal insufficiency (serum creatinine \> 2.0 mg/dl) Active GIT hemorrhage

Protocol

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 100, 'type': 'ACTUAL'}}

Updated at

2023-05-09

1 organization

1 product

1 drug

1 indication

Organization

Drug

Indication

Product